| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2024-09-09 22:09:59 UTC |
|---|
| Updated at | 2024-09-09 22:10:00 UTC |
|---|
| NP-MRD ID | NP0334096 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | 9-cis-Retinoic acid |
|---|
| Description | 9-Cis-retinoic acid is an active retinoid that regulates expression of retinoid responsive genes, serving as ligand for two classes of ligand-dependent transcription factors, the retinoic acid receptors and retinoid X receptors. Retinoids (vitamin A and its analogs) are essential dietary substances that are needed by mammals for reproduction, normal embryogenesis, growth, vision, and maintaining normal cellular differentiation and the integrity of the immune system. Within cells, retinoids regulate gene transcription acting through ligand-dependent transcription factors, the retinoic acid receptors (RARs), and the retinoid X receptors (RXRs). All-trans-retinoic acid binds only to RARs with high affinity, whereas its 9-cis isomer binds with high affinity to both RARs and RXRs. The actions of all-trans- and 9-cis-retinoic acid in regulating cellular responses are distinct and not interchangeable. (PMID: 9115228 ) [HMDB] |
|---|
| Structure | C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+ |
|---|
| Synonyms | | Value | Source |
|---|
| (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid | ChEBI | | (all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid | ChEBI | | 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid | ChEBI | | 3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-all-trans-tetraenoic acid | ChEBI | | 3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2E,4E,6E,8E-tetraenoic acid | ChEBI | | AGN 100335 | ChEBI | | all-(e)-Retinoic acid | ChEBI | | all-trans Retinoic acid | ChEBI | | all-trans-beta-Retinoic acid | ChEBI | | all-trans-Tretinoin | ChEBI | | all-trans-Vitamin a acid | ChEBI | | all-trans-Vitamin a1 acid | ChEBI | | Altreno | ChEBI | | Atralin | ChEBI | | Avita | ChEBI | | beta-Retinoic acid | ChEBI | | Betarretin | ChEBI | | Biacna | ChEBI | | Cordes vas | ChEBI | | Dermairol | ChEBI | | Refissa | ChEBI | | Renova | ChEBI | | Retin-a | ChEBI | | Retinoic acid | ChEBI | | Retisol-a | ChEBI | | Ro 1-5488 | ChEBI | | Stieva-a | ChEBI | | trans-Retinoic acid | ChEBI | | Tretin m | ChEBI | | Tretinoin | ChEBI | | Tretinoina | ChEBI | | Tretinoine | ChEBI | | Tretinoinum | ChEBI | | Tri-luma | ChEBI | | Veltin | ChEBI | | Vesanoid | ChEBI | | Vitamin a acid | ChEBI | | Vitinoin | ChEBI | | all-trans-Retinoate | Kegg | | 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl) | Kegg | | Retin a | Kegg | | (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoate | Generator | | (all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate | Generator | | 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoate | Generator | | 3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-all-trans-tetraenoate | Generator | | 3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2E,4E,6E,8E-tetraenoate | Generator | | all-(e)-Retinoate | Generator | | all-trans Retinoate | Generator | | all-trans-b-Retinoate | Generator | | all-trans-b-Retinoic acid | Generator | | all-trans-beta-Retinoate | Generator | | all-trans-Β-retinoate | Generator | | all-trans-Β-retinoic acid | Generator | | b-Retinoate | Generator | | b-Retinoic acid | Generator | | beta-Retinoate | Generator | | Β-retinoate | Generator | | Β-retinoic acid | Generator | | Retinoate | Generator | | trans-Retinoate | Generator | | 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoate (ecl) | Generator | | Eudyna | HMDB | | Solage | HMDB | | (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate | HMDB | | Tretinoin zinc salt | HMDB | | trans Retinoic acid | HMDB | | Acid, all-trans-retinoic | HMDB | | Salt, tretinoin sodium | HMDB | | beta all trans Retinoic acid | HMDB | | beta-all-trans-Retinoic acid | HMDB | | Acid, vitamin a | HMDB | | Potassium salt, tretinoin | HMDB | | Sodium salt, tretinoin | HMDB | | Acid, beta-all-trans-retinoic | HMDB | | Tretinoin potassium salt | HMDB | | Zinc salt, tretinoin | HMDB | | Acid, retinoic | HMDB | | Acid, trans-retinoic | HMDB | | Salt, tretinoin potassium | HMDB | | Salt, tretinoin zinc | HMDB | | Tretinoin sodium salt | HMDB | | all trans Retinoic acid | HMDB | | Retin-a micro | HMDB | | Tretin-X | HMDB | | all-trans-Retinoic acid | MeSH |
|
|---|
| Chemical Formula | C20H28O2 |
|---|
| Average Mass | 300.4420 Da |
|---|
| Monoisotopic Mass | 300.20893 Da |
|---|
| IUPAC Name | (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid |
|---|
| Traditional Name | tretinoin |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |
|---|
| InChI Identifier | InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+ |
|---|
| InChI Key | SHGAZHPCJJPHSC-YCNIQYBTSA-N |
|---|
| Experimental Spectra |
|---|
|
| | Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, CDCl3, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | Not Available |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as retinoids. These are oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Prenol lipids |
|---|
| Sub Class | Retinoids |
|---|
| Direct Parent | Retinoids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Retinoic acid
- Diterpenoid
- Retinoid skeleton
- Medium-chain fatty acid
- Branched fatty acid
- Methyl-branched fatty acid
- Fatty acyl
- Unsaturated fatty acid
- Fatty acid
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Hydrocarbon derivative
- Organooxygen compound
- Organic oxide
- Organic oxygen compound
- Carbonyl group
- Aliphatic homomonocyclic compound
|
|---|
| Molecular Framework | Aliphatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Mertz JR, Shang E, Piantedosi R, Wei S, Wolgemuth DJ, Blaner WS: Identification and characterization of a stereospecific human enzyme that catalyzes 9-cis-retinol oxidation. A possible role in 9-cis-retinoic acid formation. J Biol Chem. 1997 May 2;272(18):11744-9. doi: 10.1074/jbc.272.18.11744. [PubMed:9115228 ]
- Salekeen R, Siam MHB, Sharif DI, Lustgarten MS, Billah MM, Islam KMD: In silico insights into potential gut microbial modulation of NAD+ metabolism and longevity. J Biochem Mol Toxicol. 2021 Dec;35(12):e22925. doi: 10.1002/jbt.22925. Epub 2021 Sep 27. [PubMed:34580953 ]
- Liu Y, Yu F, Dai S, Meng T, Zhu Y, Qiu G, Wen L, Zhou X, Yuan H, Hu F: All-Trans Retinoic Acid and Doxorubicin Delivery by Folic Acid Modified Polymeric Micelles for the Modulation of Pin1-Mediated DOX-Induced Breast Cancer Stemness and Metastasis. Mol Pharm. 2021 Nov 1;18(11):3966-3978. doi: 10.1021/acs.molpharmaceut.1c00220. Epub 2021 Sep 27. [PubMed:34579532 ]
- Lu CH, Li KJ, Wu CH, Shen CY, Kuo YM, Hsieh SC, Yu CL: The FcgammaRIII Engagement Augments PMA-Stimulated Neutrophil Extracellular Traps (NETs) Formation by Granulocytes Partially via Cross-Talk between Syk-ERK-NF-kappaB and PKC-ROS Signaling Pathways. Biomedicines. 2021 Sep 1;9(9):1127. doi: 10.3390/biomedicines9091127. [PubMed:34572313 ]
- Huang QS, Liu Y, Wang JB, Peng J, Hou M, Liu H, Feng R, Wang JW, Xu LP, Wang Y, Huang XJ, Zhang XH: All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Haematol. 2021 Oct;8(10):e688-e699. doi: 10.1016/S2352-3026(21)00240-4. [PubMed:34560012 ]
- Gabarin N, Arnold DM: All-trans retinoic acid for treating immune thrombocytopenia: new purpose for an old drug? Lancet Haematol. 2021 Oct;8(10):e672-e673. doi: 10.1016/S2352-3026(21)00269-6. [PubMed:34560008 ]
- Nunes RAB, Abdo ANR, da Costa LMA, Skromov de Albuquerque A: Acute myocarditis in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin: a possible relationship with the differentiation syndrome or early anthracycline cardiotoxicity? Hematol Transfus Cell Ther. 2023 Jan-Mar;45(1):127-130. doi: 10.1016/j.htct.2021.06.016. Epub 2021 Sep 14. [PubMed:34548260 ]
- Dembitz V, Lalic H, Tomic B, Smoljo T, Batinic J, Dubravcic K, Batinic D, Bedalov A, Visnjic D: All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16. Int J Hematol. 2022 Jan;115(1):43-53. doi: 10.1007/s12185-021-03224-5. Epub 2021 Sep 21. [PubMed:34546543 ]
|
|---|